A systematic review of economic evaluation of sequential of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in elderly people

Main Article Content

Wiwat Thavornwattanayong
Katchapa Ratthanaphongtara
Kusuma Phoyen
Pichamol Suwankanit
Tanawan Kampanthong

Abstract

This research aimed to conduct a systematic review of studies that involve the administration of sequential pneumococcal vaccines from an economic perspective. The relevant published economic evaluations were sourced from PubMed, ScienceDirect, Cochrane Library, Scopus, and Health Intervention and Technology Assessment Program databases. This review included national and international literature published between 2012 and 2019. The quality of the research was evaluated using the consolidated health economic evaluation reporting standards checklist. Four studies that met the inclusion criteria were included in this research work. The results showed that sequential vaccination was more cost effective than a single dose of 23-valent pneumococcal polysaccharide vaccine (PPV23), which contrasted with the recommendations of Advisory Committee on Immunization Practices 2019 and Centers for Disease Control and Prevention 2020. The factors determining the economic value of these vaccines are the effectiveness of the vaccine, the coverage of the pneumococcal vaccination in childhood, indirect effects of the pneumococcal vaccination in children that can reduce the incidence of disease, and the incidence of invasive pneumococcal disease or non-bacteremic pneumococcal pneumonia in the elderly. Administering a sequence of vaccinations in the elderly may be more appropriate and beneficial than providing only a single dose of PPV23 vaccine, because of the generally low vaccination coverage of 13-valent pneumococcal conjugate vaccine during childhood. This study may be used as a basis for decision making on the pneumococcal vaccination recommendation for the elderly in Thailand.

Downloads

Download data is not yet available.

Article Details

Section
Health sciences

References

Atwood, M., Beausoleil, L., Breton, M. C., Laferriere, C., Sato, R., and Weycker, D. (2018). Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults. Canadian Journal of Public Health, 109(5-6), 756-768.

Bennett, N. M., Whitney, C. G., Moore, M., Pilishvili, T., and Dooling, K. L. (2012). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 61(40). 816-819.

Bureau of Epidemiology, Department of Disease Control Ministry of Public Health. (2019). Report disease in the surveillance system 506. [Online URL: https://www.boe.moph.go.th/boedb/surdata/506wk/y62/d31_3862.pdf] accessed on July 6, 2019.

Centers for Disease Control and Prevention. (2019). Adults protect yourself with pneumococcal vaccines. [Online URL: https://www.cdc.gov/features/adult-pneumococcal/index.html] accessed on August 11, 2019.

Centers for Disease Control and Prevention. (2017). Pneumococcal disease. [Online URL: https://www.cdc.gov/pneumococcal/about/prevention.html] accessed on August 11, 2019.

Centers for Disease Control and Prevention. (2019). Streptococcus pneumoniae. [Online URL: https://www.cdc.gov/pneumococcal/clinicians/streptococcuspneumoniae.html] accessed on July 6, 2019.

Centers for Disease Control and Prevention. (2013). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 62(25), 521-524.

Choi, M. J., Kang, S. O., Oh, J. J., Park, S. B., Kim, M. J., and Cheong, H. J. (2018). Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea. Human Vaccines & Immunotherapeutics, 14(8), 1914-1922.

Chokephaibulkit, K., Larpphra, K., Mekmallika, J., Nakboonnum, T., and Tungsathapornphong, A. (2013). Vaccine Guidelines and Immunization Promotion, Bangkok: Ratchapatsuansunandha, pp. 179-188.

European Centre for Disease Prevention and Control. (2017). Invasive pneumococcal disease. [Online URL: https://www.ecdc.europa.eu/en/publica-tions-data/invasive-pneumococcal-disease-annual-epidemiologicalreport-2017] accessed on July 6, 2019.

Greenberg, R. N., Gurtman, A., Frenck, R. W., Strout, C., Jansen, K. U., Trammel, J., Scott, D. A., Emini, E. A., Gruber, W. C., and Schmoele-Thoma, B. (2014). Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60-64 years of age. Vaccine, 32(20), 2364-2374.

Heo, J. Y., Seo, Y. B., Choi, W. S., Lee, J., Noh, J. Y., Jeong, H. W., Kim, W. J., Kim, M. J., Lee, H. Y., and Song, J. Y. (2017). Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PloS ONE, 12(5), e0177342.

Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., and Loder, E. (2013). Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: a report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health, 16(2), 231-250.

Jackson, L. A., Gurtman, A., van Cleeff, M., Jansen, K. U., Jayawardene, D., Devlin, C., Scott, D. A., Emini, E. A., Gruber, W. C., and Schmoele-Thoma, B. (2013a). Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine, 31(35), 3577-3584.

Jackson, L. A., Gurtman, A., Rice, K., Pauksens, K., Greenberg, R. N., Jones, T. R., Scott, D. A., Emini, E. A., Gruber, W. C., and Schmoele-Thoma, B. (2013b). Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine, 31(35), 3585-3593.

Jackson, L. A., Gurtman, A., Cleeff, M., Frenck, R. W., Treanor, J., Jansen, K. U., Scott, D. A., Emini, E. A., Gruber, W. C., and Schmoele-Thoma, B. (2013c). Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine, 31(35), 3594-3602.

Jung, S. M., Lee, H., and Nishiura, H. (2018). The impact of pneumococcal vaccination on pneumonia mortality among the elderly in Japan: a difference-in-difference study. PeerJ, 6, e6085.

Leventer-Roberts, M., Feldman, B. S., Brufman, I., Cohen-Stavi, C. J., Hoshen, M., and Balicer, R. D. (2015). Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study. Clinical Infectious Diseases, 60(10), 1472-1480.

Matanock, A., Lee, G., Gierke, R., Kobayashi, M., Leidner, A., and Pilishvili, T. (2019). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report, 68(46), 1069-1075.

Moher, D., Liberati, A., Tetzlaff J., and Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS MEDICINE, 6(7), 1-6.

Namkoong, H., Ishii, M., Funatsu, Y., Kimizuka, Y., Yagi, K., Asami, T., Asakura, T., Suzuki, S., Kamo, T., Fujiwara, H., Tasaka, S., Betsuyaku, T., and Hasegawa, N. (2016). Theory and strategy for pneumococcal vaccines in the elderly. Human Vaccines & Immunotherapeutics, 12(2), 336-343.

National Centre for immunization Research and Surveillance. (2018). Pneumococcal vaccines for Australians. [Online URL: http://www.ncirs.org.au/sites/default/files/2018-12/pneumococcal-fact-sheet_September2018_Final.pdf] accessed on August 27, 2019.

Oberdorfer, P. (2019). Community immunity. [Online URL: http://pidst.or.th/userfiles/62_Community%20immunity.pdf] accessed on August 27, 2019.

Peterson, J. T., Stacey, H. L., MacNair, J. E., Li, J., Hartzel, J. S., Sterling, T. M., Benner, P., Tamms, G. M., and Musey, L. K. (2019). Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Human Vaccines & Immunotherapeutics, 15(3), 540-548.

Phongphet, P., and Wirotsaengthong, M. (2019). Pneumococcalvaccines. [Online URL: https://ccpe.pharmacycouncil.org/showfile.php?file=635] accessed on August 12, 2020.

Shiramoto, M., Hanada, R., Juergens, C., Shoji, Y., Yoshida, M., Ballan, B., Cooper, D., Gruber, W. C., Scott, D. A., and Schmoele-Thoma, B. (2015). Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Human Vaccines & Immunotherapeutics, 11(9), 2198-2206.

Shiri, T., Khan, K., Keaney, K., Mukherjee, G., McCarthy, N. D., and Petrou, S. (2019). Pneumococcal disease: a systematic review of health utilities, resource use, costs, and economic evaluations of interventions. Value in Health, 22(11), 1329-1344.

Smith, K. J., Wateska, A. R., Nowalk, M. P., Raymund, M., Lee, B. Y., and Zimmerman, R. K. (2013). Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults. American Journal of Preventive Medicine, 44(4), 373-381.

Tomczyk, S., Bennett, N. M., Stoecker, C., Gierke, R., Moore, M. R., Whitney, C. G., Hadler, S., and Pilishvili, T. (2014). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged≥ 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 63(37), 822-825.

World Health Organization. (2018). Pneumococcal conjugate (PCV3) immunization coverage estimates by country. [Online URL: http://apps.who.int/gho/data/view.main.PCV3v?lang=en] accessed on January 17, 2020.